28th Mar 2011 14:27
RNS Number : 7506D
AGI Therapeutics plc
28 March 2011
AGI Therapeutics plc
('AGI' or the 'Company')
Directors' Dealing
AGI was informed on 25 March 2011 that David Kelly, a Director and Chief Financial Officer of AGI, purchased 550,000 ordinary shares of €0.01 each ("Ordinary Share") in the share capital of the Company at a price of €0.045 per Ordinary Share on 25 March 2011.
Following this purchase, David Kelly's beneficial shareholding in the Company is 655,000 Ordinary Shares.
Contact Information:
David G. Kelly, Chief Financial Officer Tel: +353 1 449 3254
This information is provided by RNS
The company news service from the London Stock Exchange
Related Shares:
Potentially Ai